智通财经网·2025-08-29 06:33Core Viewpoint - Tiger Med (03347) experienced a decline of over 3%, with a current price of HKD 46.42 and a trading volume of HKD 203 million [1] Financial Performance - For the first half of 2025, the company reported revenue of RMB 3.25 billion, a year-on-year decrease of 3.21% [1] - The net profit attributable to shareholders was RMB 383 million, down 22.22% year-on-year [1] - In Q2, the company achieved revenue of RMB 1.686 billion, a slight decline of 0.69% year-on-year [1] - The net profit for Q2 was RMB 218 million, reflecting a year-on-year decrease of 15.48% [1] Analyst Insights - UBS noted that the Q2 revenue fell by 0.7% to RMB 1.69 billion, which is an improvement from a 5.8% decline in Q1, but still below expectations [1] - The net profit for Q2 decreased by 15.5% to RMB 218 million, compared to a 29.6% decline in Q1, also falling short of market expectations [1] Future Outlook - The company maintains its full-year guidance, expecting revenue to grow in the high single digits year-on-year [1] - The gross margin is anticipated to recover quarterly, and the recurring net profit margin is expected to improve [1] - Due to growth in new orders in Q1, the full-year revenue forecast has been raised to approximately 15%, up from over 10% previously [1] - The company expects net operating cash flow to reach around RMB 1 billion this year and plans to enhance shareholder returns through dividends or stock buybacks [1]